+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Anaplastic Thyroid Cancer Drugs Market 2019-2023 - Product Image

Global Anaplastic Thyroid Cancer Drugs Market 2019-2023

  • ID: 4791001
  • Report
  • June 2019
  • Region: Global
  • 124 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Eisai Co. Ltd.
  • Novartis AG
  • MORE
Global Anaplastic Thyroid Cancer Drugs Market: About this market

The anaplastic thyroid cancer drugs market analysis considers sales from both chemotherapy and novel therapy. Our report also finds the sales of anaplastic thyroid cancer drugs in North America, Europe, Asia, and ROW. In 2018, chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of thyroid cancer will play a significant role in the chemotherapy segment to maintain its market position. Also, our global anaplastic thyroid cancer drugs market report looks at factors such as the introduction of targeted therapies, and the rising geriatric population and high prevalence of thyroid cancer. However, the adverse effects of chemotherapy, availability of substitutes, and stringent regulations may hamper the growth of the anaplastic thyroid cancer drugs industry over the forecast period.

Global anaplastic thyroid cancer drugs market: Overview

Introduction of targeted therapies

The adverse effects associated with the off-label medicines available in the market has led to the development of targeted therapies for cancer treatments. The mutations of the BRAF gene cause most of the cases of anaplastic thyroid cancer. Hence, BRAF kinase inhibitors are one of the most foreseen small molecule targeted therapy drugs for the treatment of anaplastic thyroid cancer. Thus, the introduction of targeted therapies will lead to the expansion of the anaplastic thyroid cancer drugs market at a CAGR of more than 4% during the forecast period.

Reimbursement policies for chemotherapy

The high cost of off-label therapies such as chemotherapy remains a challenge for patients and the healthcare system. To overcome this challenge, governments and NGOs are focusing on providing financial assistance for the treatment of various cancer indications, including anaplastic thyroid cancer. This encourages many patients to avail off-label treatments, which will lead to an increase in the patient base. Thus, the increasing availability of reimbursement policies for chemotherapy will fuel market growth during the forecast period.

Competitive Landscape

With the presence of several major players, the global anaplastic thyroid cancer drugs market is moderately fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anaplastic thyroid cancer drugs manufacturers, that include Bristol-Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Johnson & Johnson Services Inc., and Novartis AG.

Also, the anaplastic thyroid cancer drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Eisai Co. Ltd.
  • Novartis AG
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Chemotherapy - Market size and forecast 2018-2023
  • Novel therapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11:   MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Eisai Co. Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List Of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 21: Novel therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Novel therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Patient assistance programs
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Global growth in geriatric population in the last five years (%)
Exhibit 43: Adverse effects associated with available drugs for treatment of anaplastic thyroid cancer
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Drug development pipeline: Late-stage molecules for anaplastic thyroid cancer
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 52: Bristol-Myers Squibb Co. - Product segments
Exhibit 53: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 54: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 55: Bristol-Myers Squibb Co. - Key offerings
Exhibit 56: Bristol-Myers Squibb Co. - Key customers
Exhibit 57: Celgene Corp. - Vendor overview
Exhibit 58: Celgene Corp. - Business segments
Exhibit 59: Celgene Corp. - Organizational developments
Exhibit 60: Celgene Corp. - Geographic focus
Exhibit 61: Celgene Corp. - Key offerings
Exhibit 62: Celgene Corp. - Key customers
Exhibit 63: Eisai Co. Ltd. - Vendor overview
Exhibit 64: Eisai Co. Ltd. - Business segments
Exhibit 65: Eisai Co. Ltd. - Organizational developments
Exhibit 66: Eisai Co. Ltd. - Geographic focus
Exhibit 67: Eisai Co. Ltd. - Segment focus
Exhibit 68: Eisai Co. Ltd. - Key offerings
Exhibit 69: Eisai Co. Ltd. - Key customers
Exhibit 70: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 71: Johnson & Johnson Services, Inc. - Business segments
Exhibit 72: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 73: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 74: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 75: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 76: Johnson & Johnson Services, Inc. - Key customers
Exhibit 77: Novartis AG - Vendor overview
Exhibit 78: Novartis AG - Business segments
Exhibit 79: Novartis AG - Organizational developments
Exhibit 80: Novartis AG - Geographic focus
Exhibit 81: Novartis AG - Segment focus
Exhibit 82: Novartis AG - Key offerings
Exhibit 83: Novartis AG - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Eisai Co. Ltd.
  • Novartis AG
  • MORE
The following companies are recognised as the key players in the global anaplastic thyroid cancer drugs market: Bristol-Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Johnson & Johnson Services Inc., and Novartis AG.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the reimbursement policies for chemotherapy.”

According to the report, one of the major drivers for this market is the introduction of targeted therapies.

Further, the report states that one of the major factors hindering the growth of this market is the adverse effects of chemotherapy.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Eisai Co. Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
Note: Product cover images may vary from those shown
Adroll
adroll